OBJECTIVE: To compare the clinical effects between individual antiplatelet therapy guided by @entity4433 genetic testing and conventional dual antiplatelet therapy in @entity1 with @entity453 after percutaneous coronary intervention. METHODS: In total of 628 @entity453 @entity1 who had undergone successful percutaneous coronary intervention were included in this study. @entity1 were consecutively divided into routine group (n = 319) and individual group (n = 309) because of weather received @entity4433 genetic testing. The individual group was divided again into extensive metabolizer group, intermediate metabolizer group, and poor metabolizer group according to @entity4433 genotype. Then extensive metabolizer group received 75 mg daily of @entity1397 , intermediate metabolizer group received 150 mg daily of @entity1397 , and poor metabolizer group received @entity3077 90 mg twice daily. Routine group was treated with @entity1397 75 mg daily conventionally. The primary end points were defined as major adverse cardiovascular events (MACE), namely a composite of death from any cause, @entity583 , or target vessel revascularization. Safety end points were @entity548 events classified by GUSTO. RESULTS: All the 628 @entity1 were followed for an average of 12 months and clinical outcomes were analyzed at 1, 6, and 12 months after discharge. The morbidity rates of MACE in individual group were all lower than those in routine group at 1, 6, and 12 months (1.3% vs. 5.6%, P = 0.003; 3.2% vs. 7.8%, P = 0.012; 4.2% vs. 9.4%, P = 0.010). No significant difference in the rates of @entity548 was found between the 2 groups (P > 0.05). Even performed a multivariate logistic regression analysis, the benefit of individual antiplatelet therapy remained. CONCLUSION: Individual antiplatelet therapy guided by @entity4433 genetic testing significantly reduced the rate of MACE without an increase in the rate of @entity548 in the near term in this Chinese population.

Clinical Value of XXXX Genetic Testing for Guiding the Antiplatelet Therapy in a Chinese Population.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction'] @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding'] @entity4433 :: ('1557', 'Gene') :: ['CYP2C19'] @entity1397 :: ('MESH:C055162', 'Chemical') :: ['clopidogrel'] @entity3077 :: ('MESH:C503700', 'Chemical') :: ['ticagrelor'] @entity453 :: ('MESH:D003324', 'Disease') :: ['coronary artery disease']
@entity4433 :: (1557,Gene) :: ['CYP2C19']
